These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. An exploratory study of the consistency of balance control and the mobility of people with Parkinson's disease (PD) between medication doses. Campbell F; Ashburn A; Thomas P; Amar K Clin Rehabil; 2003 May; 17(3):318-24. PubMed ID: 12735540 [TBL] [Abstract][Full Text] [Related]
44. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease. Martínez-Martín P; Hernández B; Ricart J; Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686 [TBL] [Abstract][Full Text] [Related]
45. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551 [TBL] [Abstract][Full Text] [Related]
46. C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population. Cannas A; Solla P; Borghero G; Floris GL; Chio A; Mascia MM; Modugno N; Muroni A; Orofino G; Di Stefano F; Calvo A; Moglia C; Restagno G; Meloni M; Farris R; Ciaccio D; Puddu R; Vacca MI; Melis R; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Marrosu MG; Marrosu F J Neurol; 2015 Nov; 262(11):2498-503. PubMed ID: 26275564 [TBL] [Abstract][Full Text] [Related]
47. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. LeWitt P; Oakes D; Cui L Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976 [TBL] [Abstract][Full Text] [Related]
48. What are the issues facing Parkinson's disease patients at ten years of disease and beyond? Data from the NPF-QII study. Hassan A; Wu SS; Schmidt P; Malaty IA; Dai YF; Miyasaki JM; Okun MS Parkinsonism Relat Disord; 2012 Dec; 18 Suppl 3():S10-4. PubMed ID: 22776044 [TBL] [Abstract][Full Text] [Related]
49. Do patients with late-stage Parkinson's disease still respond to levodopa? Fabbri M; Coelho M; Abreu D; Guedes LC; Rosa MM; Costa N; Antonini A; Ferreira JJ Parkinsonism Relat Disord; 2016 May; 26():10-6. PubMed ID: 26972527 [TBL] [Abstract][Full Text] [Related]
50. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335 [TBL] [Abstract][Full Text] [Related]
51. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
52. Assessment of striatal & postural deformities in patients with Parkinson's disease. Pandey S; Kumar H Indian J Med Res; 2016 Nov; 144(5):682-688. PubMed ID: 28361820 [TBL] [Abstract][Full Text] [Related]
53. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Winge K; Werdelin LM; Nielsen KK; Stimpel H Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192 [TBL] [Abstract][Full Text] [Related]
54. Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson's disease? Suzuki K; Miyamoto T; Miyamoto M; Uchiyama T; Hirata K J Neurol Sci; 2018 Feb; 385():131-133. PubMed ID: 29406892 [TBL] [Abstract][Full Text] [Related]
55. Gait and balance disorders in Parkinson's disease: impaired active braking of the fall of centre of gravity. Chastan N; Do MC; Bonneville F; Torny F; Bloch F; Westby GW; Dormont D; Agid Y; Welter ML Mov Disord; 2009 Jan; 24(2):188-95. PubMed ID: 18973252 [TBL] [Abstract][Full Text] [Related]
56. Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease. Coban A; Hanagasi HA; Karamursel S; Barlas O Br J Neurosurg; 2009 Feb; 23(1):23-9. PubMed ID: 19234905 [TBL] [Abstract][Full Text] [Related]
57. Balance in Parkinson's disease under static and dynamic conditions. Nardone A; Schieppati M Mov Disord; 2006 Sep; 21(9):1515-20. PubMed ID: 16817196 [TBL] [Abstract][Full Text] [Related]
58. Objective Gait and Balance Impairments Relate to Balance Confidence and Perceived Mobility in People With Parkinson Disease. Curtze C; Nutt JG; Carlson-Kuhta P; Mancini M; Horak FB Phys Ther; 2016 Nov; 96(11):1734-1743. PubMed ID: 27149959 [TBL] [Abstract][Full Text] [Related]
59. [The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study]. Datieva VK; Makotrova TA; Levin OS Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):13-9. PubMed ID: 23250605 [TBL] [Abstract][Full Text] [Related]
60. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease. Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]